Screener
Celldex Therapeutics CLDX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Other assets | (2,076) | 447 |
| Accounts payable and accrued expenses | 9,850 | (6,632) |
| Other liabilities | (1,848) | (1,724) |
| Net cash used in operating activities | (122,998) | (98,377) |
| Cash flows from investing activities: | ||
| Sales and maturities of marketable securities | 283,876 | 367,873 |
| Purchases of marketable securities | (462,461) | (274,080) |
| Acquisition of property and equipment | (4,818) | (993) |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's operating cash flow?
- Celldex Therapeutics (CLDX) reported operating cash flow of -$57.41M in Q2 2026.
- How has Celldex Therapeutics's operating cash flow changed year-over-year?
- Celldex Therapeutics's operating cash flow decreased by 30.5% year-over-year, from -$44.01M to -$57.41M.
- What is the long-term trend for Celldex Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Celldex Therapeutics's operating cash flow has grown at a 36.4% compound annual growth rate (CAGR), from -$60.91M to -$210.95M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Celldex Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude